Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress Read more about Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress
Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017 Read more about Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017
Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy Read more about Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy
Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th Read more about Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th
Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy Read more about Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy
Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy Read more about Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16 Read more about Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16
Aimmune Therapeutics Announces First Quarter 2017 Financial Results Read more about Aimmune Therapeutics Announces First Quarter 2017 Financial Results
Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer Read more about Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results Read more about Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
